GRI vs POAS Comparison

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.